Centogene N.V. (Nasdaq: CNTG), the essential life science partner
for data-driven answers in rare and neurodegenerative diseases,
today announced that it has extended and expanded the observational
EFRONT Study to advance the genetic understanding of frontotemporal
dementia (FTD).
The announcement comes in the lead-up to Rare Disease Day (RDD)
on February 28. Since 2008, RDD has been held annually on the last
day of February and includes a range of activities and initiatives
throughout the month. Bringing together physicians, patient
organizations, researchers, medical companies, and of course, rare
disease patients from around the world, RDD raises awareness and
serves as an opportunity to generate change for the rare disease
community.
Leveraging CENTOGENE’s extensive network of approximately 30,000
active physicians, the EFRONT study aims to enroll and complete
data-rich genetic testing for over 2,500 FTD diagnosed or suspected
patients to learn more about the genetic makeup of the disease. As
part of this ongoing work, the EFRONT study will expand its efforts
across seven countries – increasing access to clinicians actively
engaged in FTD research. The EFRONT study is being conducted with
support from Alector, Inc., a clinical-stage biotechnology company
pioneering immuno-neurology.
EFRONT study participants with genetic mutations in the
progranulin (GRN) gene will have the option to enroll in Alector’s
Phase 3 INFRONT-3 clinical trial of latozinemab, an investigational
therapeutic candidate designed to increase progranulin levels for
the treatment of FTD.
“Frontotemporal dementia is a rapidly progressing
neurodegenerative disease, with no FDA-approved treatments,” said
Kim Stratton, Chief Executive Officer at CENTOGENE. “At CENTOGENE,
we are committed to establishing a more inclusive and comprehensive
approach from the very beginning of the pipeline to the end. This
can only be achieved using diverse knowledge of rare and
neurodegenerative diseases, which can be sourced from the CENTOGENE
Biodatabank, from diagnostics to drug discovery, development, and
commercialization.”
Alector is a clinical-stage biotechnology company pioneering
immuno-neurology, a novel therapeutic approach for the treatment of
neurodegenerative diseases. Alector is developing a broad portfolio
of innate immune system programs, designed to functionally repair
genetic mutations that cause dysfunction of the brain’s immune
system and enable the rejuvenated immune cells to counteract
emerging brain pathologies.
“Frontotemporal dementia is a devastating disease for which new
treatment options are urgently needed,” said Gary Romano, M.D.,
Ph.D., Chief Medical Officer of Alector. “The EFRONT study helps us
understand the genetic factors of the disease with the ultimate
goal of advancing therapeutic options for patients living with
FTD.”
About Frontotemporal Dementia (FTD)
FTD is a rare neurodegenerative disease and the most common form
of dementia for people under the age of 60. It affects an estimated
50,000 to 60,000 people in the United States and roughly 110,000 in
the European Union. There are multiple heritable forms of FTD,
including FTD-GRN. Patients with FTD frequently develop symptoms
such as behavioral changes, lapses in judgment, and diminished
language skills when they are in their 40’s and 50’s, with the
disease running its course in 7-10 years. There are no FDA-approved
treatment options available for any form of FTD.
About the EFRONT Study
The EFRONT Study is a single visit, multi-center,
non-interventional study that investigates the prevalence of
genetic etiologies in frontotemporal dementia (FTD) by genotyping
patients diagnosed with or suspected of FTD.
FTD is a genetically and pathologically heterogeneous
neurodegenerative disease caused by the loss or damage of nerve
cells in the brain’s frontal and temporal lobes. As a result, there
are abnormalities in behavior, personality, and language
comprehension problems, like lack of interest, judgment, loss of
empathy, and apathy.
To learn more about how you can enroll in the EFRONT Study,
visit ClinicalTrials.gov.
About Rare Disease Day (RDD)
RDD has been held annually on the last day of February
since 2008 – approaching its 16-year anniversary and underlining
the incredible efforts of the rare disease community.
Traditionally, RDD shines a spotlight on the extraordinary
challenges posed by these often serious and hereditary conditions –
raising awareness amongst healthcare providers, policymakers, and
the general public.
To learn more about rare diseases and how you can get involved
with RDD 2023, visit: rarediseaseday.org
About CENTOGENE
CENTOGENE’s mission is to provide data-driven, life-changing
answers to patients, physicians, and pharma companies for rare and
neurodegenerative diseases. We integrate multiomic technologies
with the CENTOGENE Biodatabank – providing dimensional analysis to
guide the next generation of precision medicine. Our unique
approach enables rapid and reliable diagnosis for patients,
supports a more precise physician understanding of disease states,
and accelerates and de-risks targeted pharma drug discovery,
development, and commercialization.
Since our founding in 2006, CENTOGENE has been offering rapid
and reliable diagnosis – building a network of approximately 30,000
active physicians. Our ISO, CAP, and CLIA certified multiomic
reference laboratories in Germany utilize Phenomic, Genomic,
Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets.
This data is captured in our CENTOGENE Biodatabank, with nearly
700,000 patients represented from over 120 highly diverse
countries, over 70% of whom are of non-European descent. To date,
the CENTOGENE Biodatabank has contributed to generating novel
insights for more than 260 peer-reviewed publications.
By translating our data and expertise into tangible insights, we
have supported over 50 collaborations with pharma partners.
Together, we accelerate and de-risk drug discovery, development,
and commercialization in target & drug screening, clinical
development, market access and expansion, as well as offering
CENTOGENE Biodatabank Licenses and Insight Reports to enable a
world healed of all rare and neurodegenerative diseases.
To discover more about our products, pipeline, and
patient-driven purpose, visit www.centogene.com and follow us on
LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” are
generally intended to identify forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause
CENTOGENE’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others,
negative economic and geopolitical conditions and instability and
volatility in the worldwide financial markets, possible changes in
current and proposed legislation, regulations and governmental
policies, pressures from increasing competition and consolidation
in our industry, the expense and uncertainty of regulatory
approval, including from the U.S. Food and Drug Administration, our
reliance on third parties and collaboration partners, including our
ability to manage growth, execute our business strategy and enter
into new client relationships, our dependency on the rare disease
industry, our ability to manage international expansion, our
reliance on key personnel, our reliance on intellectual property
protection, fluctuations of our operating results due to the effect
of exchange rates, our ability to streamline cash usage, our
continued ongoing compliance with covenants linked to financial
instruments, our requirement for additional financing, or other
factors. For further information on the risks and uncertainties
that could cause actual results to differ from those expressed in
these forward-looking statements, as well as risks relating to
CENTOGENE’s business in general, see CENTOGENE’s risk factors set
forth in CENTOGENE’s Form 20-F filed on March 31, 2022, with the
Securities and Exchange Commission (the “SEC”) and subsequent
filings with the SEC. Any forward-looking statements contained in
this press release speak only as of the date hereof, and
CENTOGENE’s specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
Contact:
CENTOGENE
Ben Legg Corporate
Communications Press@centogene.com
Lennart StreibelInvestor RelationsIR@centogene.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Jul 2023 to Jul 2024